<DOC>
	<DOCNO>NCT02248961</DOCNO>
	<brief_summary>Assess compare efficacy safety Kanarb ( Fimasartan ) , manufacture Boryung Pharmaceutical Co. , Ltd , Republic Korea , tablets 60/120 mg Cozaar® ( Losartan ) , manufacture MERCK SHARP &amp; DOHME B.V. , Netherlands , tablet 50/100 mg adult patient Grade I-II arterial hypertension 12 week therapy</brief_summary>
	<brief_title>Efficacy Safety Evaluating Study Compare Kanarb ( Fimasartan ) Cozaar® ( Losartan ) Adult Patients With Grade I-II Arterial Hypertension</brief_title>
	<detailed_description>1 . To evaluate efficacy 12-week Kanarb ( Fimasartan ) , manufacture Boryung Pharmaceutical Co. , Ltd , Republic Korea , tablets 60/120 mg Cozaar® ( Losartan ) , manufacture MERCK SHARP &amp; DOHME B.V. , Netherlands , tablet 50/100 mg adult patient Grade I-II arterial hypertension . 2 . To evaluate safety 12-week Kanarb ( Fimasartan ) , manufacture Boryung Pharmaceutical Co. , Ltd , Republic Korea , tablets 60/120 mg Cozaar® ( Losartan ) , manufacture MERCK SHARP &amp; DOHME B.V. , Netherlands , tablet 50/100 mg adult patient Grade I-II arterial hypertension . 3 . Assess pharmacokinetics parameter Kanarb ( Fimasartan ) , manufacture Boryung Pharmaceutical Co. , Ltd , Republic Korea adult patient arterial hypertension I-II stage single dose . Starting dose Kanarb ( Fimasartan ) , manufacture Boryung Pharmaceutical Co. , Ltd , Republic Korea 60 mg , orally , day morning . The plan study duration subject 18 week maximum : The screening period could take 2 week ( include 1-week `` wash-out '' period ) - screen period duration depend prior anti-hypertensive therapy : - `` naive '' subject never receive therapy ( must reflect source document ) , may randomize completion screening procedure ; - Subjects receive anti-hypertensive therapy may discontinue without prior dose reduction must undergo 7 day `` wash-out '' period , screening period take least 7 day ; - Subjects , receive anti-hypertensive therapy require dose reduction discontinuation must undergo 7 day `` wash-out '' period last dose administration , screen period consist dose reduction period `` wash-out '' period . Treatment period - 12 week . Follow-up period - 4 week . The subject visit clinical site every 4 week measure ABP . The dose double case SBP ≥140 mmHg DBP ≥90 mmHg Visit 3 ( Day 28 ) Visit 4 ( Day 56 ) . If necessary , dose study drug may increase base assessment patient 's condition perform phone contact ( Day14±3 ) . Patient may call unscheduled visit treatment adjustment ( decide individually , possibility dose titration per investigator 's judgment , indicate source document ) . When possibility , patient administrate study medication time morning . Governing condition define time drug administration subject comfort time visit research center . If laboratory test schedule , patient come research center fasting ( food prohibit 8 hour visit ) . All clinical evaluation conduct next morning take medication . On visit day patient come research center take drug , plan procedure conduct patient administrate drug .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Subjects sex age 1875 inclusively . 2 . Subjects sign write Informed Consent participation study willing adhere Protocol procedure . 3 . Subjects document diagnosis grade III primary arterial hypertension within least 3 month screen . 4 . Systolic blood pressure ( SBP ) ( seat ) Screening ( Day 14 ) For subject administer antihypertensive therapy : SBP ≤ 179 Hg For subject receive antihypertensive therapy ( call 'naïve ' patient ) : 140≥SBP ≤179 . 5 . As per investigator 's judgment , subject control arterial hypertension must benefit therapy switch Kanarb ( Fimasartan ) , manufacture Boryung Pharmaceutical Co. , Ltd , Republic Korea , tablets 60/120 mg Cozaar® ( Losartan ) , manufacture MERCK SHARP &amp; DOHME B.V. , Netherlands , . 6 . For subject administer antihypertensive drug : antihypertensive drug may safely cancel `` washout '' period accord investigator 's judgment . 7 . For woman childbearing potential : negative urine pregnancy test screening ( Day 14 ) . 8 . Systolic blood pressure ( SBP ) ( seat ) Randomization ( Day 0 ) ≥140 mmHg ≤179 mmHg . 9 . For woman childbearing potential : negative urine pregnancy test Randomization ( Day 0 ) 1 . Grade III Arterial Hypertension . 2 . Arterial hypotension ( SPB ≤100 mm Hg ) Screening ( Day 14 ) and/or Randomization ( Day 0 ) . 3 . Subjects need treatment one antihypertensive drug ( one active substance , include complex drug ) . 4 . Secondary ( symptomatic ) arterial hypertension . 5 . Known bilateral renal arterial stenosis unilateral renal arterial stenosis . 6 . Hyperpotassemia &gt; 5,0 mmol/l ( per blood biochemistry result Screening ) . 7 . Primary hyperaldosteronism . 8 . Known hypersensitivity angiotensinII receptor antagonists study drug comparator component . 9 . Contraindications use angiotensinII receptor antagonist . 10 . Myocardial infarction unstable angina , and/or acute cerebrovascular accident/transient ischemic attack , and/or percutaneous coronary intervention , and/or coronary arterial bypass graft , acute coronary artery involvement , and/or obliterative vascular atherosclerosis low extremity , and/or grade III IV retinopathy anamnesis . 11 . Clinically significant cardiac valve damage . 12 . Cardiomyopathies 13 . Chronic Heart failure ( CHF ) ( except CHF FC I NYHA ) . 14 . Creatinine clearance le 60 ml/min/1.73m2 calculate CockroftGault formula . 15 . Known moderate severe hepatic insufficiency and/or transaminase increase : AST and/or ALT ≥2*ULN . 16 . History infection ( HIV , hepatitis B C , syphilis ) . 17 . Uncontrolled Diabetes mellitus , Glycosylated hemoglobin level ( HbA1c ) &gt; 7 % . 18 . Severe systemic disease , gastrointestinal tract disease , autoimmune disorder , blood disorder condition may affect study drug ' absorption , distribution excretion . 19 . Clinically significant abnormality laboratory parameter . 20 . Drug alcohol addiction , psychiatric disorder . 21 . Medical history oncological disease within 5 year screen . 22 . Subjects biliary tract obstruction . 23 . Subjects genetic disorder , galactose intolerance , congenital lactase insufficiency glucosegalaclose malabsorption syndrome . 24 . Any acute disease progression and/or decompensation moment enrollment 25 . Necessity administer administration prohibit concomitant drug `` List Prohibited Drugs '' within 14 day enrollment 26 . Pregnancy breastfeed period ; fertile woman use adequate contraception method 27 . Participation another clinical trial within 3 month Screening . 28 . Other medical psychiatric condition lab abnormality may increase potential risk associate study participation IP administration , may affect study result interpretation per investigator 's judgment , make subject ineligible . 29 . Study site personnel Sponsor 's representative immediately involved study . 30 . Subjects , exclude study may include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>